Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Private equity funds grab smaller slice of M&A deals

Fri, 28th Mar 2014 00:00

By Freya Berry

LONDON, March 28 (Reuters) - Buyout firms are finding itharder to take part in mergers and acquisitions as the lure ofstronger equity markets persuades more funds seeking to exitassets to try their luck with a public share sale or turn tocash-rich corporate buyers.

Private equity-backed mergers and acquisitions (M&A) fell byalmost a third to $55.2 billion from a year ago, Thomson Reutersquarterly data showed on Friday.

European private equity firms accounted for 8 percent of M&Adeals in the year to date, down from 10 percent from the sameperiod last year and the lowest since 2011, although the valueof private equity-backed deals did rise in the region.

"The bottom line is that in many sectors private equity isstruggling to compete with the public markets," said JamesSimpson, Head of Sponsor M&A at UBS. "Assets that wouldnaturally have come to private equity are going to IPO."

The MSCI World Price Index surged 24 percentlast year. That has brought a rash of companies to market asthey seek to capitalise on buoyant public interest, limiting thedeals available for buyout firms.

Private equity firms are also grappling with asset priceinflation.

Valuations have risen, partly due to a scarcity of assets,because of companies turning to IPOs, but also due to a growingamount of undeployed fund capital which leaves private equityfunds paying out more as they hunt for ways to spend cash.

A report by Bain & Company this month found that undeployedcapital, or dry powder, hit $1 trillion at the end of 2013,pushed up by investors seeking returns in a world of lowinterest rates.

"Multiples have gone up," Simpson said. "You have toacclimatise to paying bigger prices, and that takes a bit oftime."

As well as expensive assets, funds are also shying away fromcompetition with huge corporate cashpiles built up since thefinancial crisis.

Last year, GlaxoSmithKline scrapped a plan to sellits drinks businesses Lucozade and Ribena in an auction whichwould have included private equity firms when Japan's SuntoryBeverage & Food muscled in.

"Whilst (investors) would continue to say this is afantastic environment in which to exit businesses, it's actuallystill proving to be a challenging environment in which to deploynew capital," said Alasdair Warren, head of European FinancialSponsors Group at Goldman Sachs.

"The IPO markets are so strong and the multiples are sohigh, that it is very difficult for sponsors to compete."

But despite the squeeze, private equity firms are confidentthat the rush to IPO will not last forever.

"It is likely that the IPO markets will remain open for sometime but how long it will last is hard to tell," said LionelAssant, Senior Managing Director and European Head of PrivateEquity at Blackstone.

"Public markets rightly demand a proven management team anda clear strategy for growth from any company floating."

Goldman Sachs led the global rankings for M&A advisorbanks with a 46.3 percent market share, while JP Morgan was top for European deals with a 32.4 percent market share, thedata showed.

There have been 271 deals in Europe so far, an increase of6.7 percent year-on-year. But the value of transactionsincluding net debt has soared 24 percent to $12.9 billion overthe same period, the data showed. (Editing by Elaine Hardcastle)

More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.